Welcome to the May 25th 2007 edition of Carnival of Biotechnology.
Finance and business development
The big news on the web is Google’s investment in 23andMe, described here by the California Biotech Law Blog.
International biotech
Business Week has an article on The Rush To Test Drugs In China. This is a story with a number of potential upsides. Drug companies are having trouble finding sufficient numbers of clinical trial participants in North America, ultimately delaying the approval of vital medicines. Many Chinese patients are in need of cutting edge medicine. By conducting clinical trials overseas (clinical trials intended for FDA approval must meet American standards of care and ethics, regardless of where they are performed), drug companies can speed approval while simultaneously helping patients overseas.
Communications
John Mack at Pharma Marketing has two interesting pieces. First, he offers some advice to GlaxoSmithKline on Avandia: Don’t do what Merck did! Next, he investigates Centocor’s “disease awareness” movie INNERSTATE.
Investing
Forbes presents an educational article on Chasing Down Biotech Zombie Stocks – biotech firms operating with minimal revenues and no real chance of sustainable growth.
That concludes this edition.
For more information, see the Carnival of Biotechnology Homepage, or submit a link for the next edition. Interested in hosting a future Carnival of Biotechnology? Let me know.